ZA859065B - 1-heteroaryl-4-aryl-pyrazolin-5-ones for use as medicaments - Google Patents

1-heteroaryl-4-aryl-pyrazolin-5-ones for use as medicaments

Info

Publication number
ZA859065B
ZA859065B ZA859065A ZA859065A ZA859065B ZA 859065 B ZA859065 B ZA 859065B ZA 859065 A ZA859065 A ZA 859065A ZA 859065 A ZA859065 A ZA 859065A ZA 859065 B ZA859065 B ZA 859065B
Authority
ZA
South Africa
Prior art keywords
pyrazolin
medicaments
heteroaryl
aryl
ones
Prior art date
Application number
ZA859065A
Other languages
English (en)
Inventor
Klaus Sasse
Michael Hammond
Friedel Seuter
Elizabeth Penzborn
Bernhard Pelster
Graham Sturton
Trevor Abram
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of ZA859065B publication Critical patent/ZA859065B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
ZA859065A 1984-11-28 1985-11-27 1-heteroaryl-4-aryl-pyrazolin-5-ones for use as medicaments ZA859065B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19843443308 DE3443308A1 (de) 1984-11-28 1984-11-28 1-heteroaryl-4-aryl-pyrazolin-5-one zur verwendung als arzneimittel

Publications (1)

Publication Number Publication Date
ZA859065B true ZA859065B (en) 1986-07-30

Family

ID=6251331

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA859065A ZA859065B (en) 1984-11-28 1985-11-27 1-heteroaryl-4-aryl-pyrazolin-5-ones for use as medicaments

Country Status (7)

Country Link
US (1) US4698344A (ja)
EP (1) EP0183159A3 (ja)
JP (1) JPS61137878A (ja)
DE (1) DE3443308A1 (ja)
ES (1) ES8801243A1 (ja)
IL (1) IL77138A0 (ja)
ZA (1) ZA859065B (ja)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK169672B1 (da) * 1985-05-20 1995-01-09 Mitsubishi Chem Ind Farmaceutiske præparater indeholdende pyrazolonderivater som aktiv bestanddel og anvendelsen af pyrazolonderivater til fremstilling af farmaceutiske præparater
USRE35801E (en) * 1985-05-20 1998-05-19 Mitsubishi Chemical Corporation Prophylactic and therapeutic composition for circulatory disorders and method of treatment
DE3527157A1 (de) * 1985-07-30 1987-02-12 Bayer Ag 1-heteroaryl-4-aryl-pyrazol-derivate
DE3718526A1 (de) * 1987-06-03 1988-12-22 Basf Ag Substituierte 5-amino-1-(pyrimidin-2-yl)-1h-pyrazole
JPH01211582A (ja) * 1988-02-16 1989-08-24 Tanabe Seiyaku Co Ltd ベンゾジオキソール誘導体
US5663416A (en) * 1990-05-22 1997-09-02 Cortech Inc. Oxidant sensitive and insensitive aromatic esters as inhibitors of human neutrophil elastase
US5214191A (en) * 1990-05-22 1993-05-25 Cortech, Inc. Oxidant sensitive and insensitive aromatic esters as inhibitors of human neutrophil elastase
GB9017351D0 (en) * 1990-08-08 1990-09-19 Wellcome Found Medicaments for treatment of atherosclerosis
DE102008020113A1 (de) 2008-04-23 2009-10-29 Bayer Schering Pharma Aktiengesellschaft Substituierte Dihydropyrazolone und ihre Verwendung
DE102005019712A1 (de) * 2005-04-28 2006-11-09 Bayer Healthcare Ag Dipyridyl-dihydropyrazolone und ihre Verwendung
DE102006050513A1 (de) * 2006-10-26 2008-04-30 Bayer Healthcare Ag Substitiuierte Dihydropyrazolone und ihre Verwendung
DE102006050515A1 (de) 2006-10-26 2008-04-30 Bayer Healthcare Ag Substituierte Dipyridiyl-dihydropyrazolone und ihre Verwendung
DE102006050516A1 (de) 2006-10-26 2008-04-30 Bayer Healthcare Ag Substituierte Dihydropyrazolone und ihre Verwendung
DE102007044032A1 (de) 2007-09-14 2009-03-19 Bayer Healthcare Ag Substituierte heterocyclische Verbindungen und ihre Verwendung
DE102007048447A1 (de) 2007-10-10 2009-04-16 Bayer Healthcare Ag Substituierte Dihydropyrazolthione und ihre Verwendung
FR2949466A1 (fr) * 2009-08-28 2011-03-04 Sanofi Aventis Derives de 2-pyridin-2-yl-pyrazol-3(2h)-one, leur preparation et leur application en therapeutique comme activateurs de hif
DE102010044131A1 (de) 2010-11-18 2012-05-24 Bayer Schering Pharma Aktiengesellschaft Substituiertes Natrium-1H-pyrazol-5-olat
CA2903875C (en) 2013-03-29 2021-07-20 Takeda Pharmaceutical Company Limited 6-(5-hydroxy-1h-pyrazol-1-yl)nicotinamide derivatives and their use as phd inhibitors
WO2019141957A1 (en) * 2018-01-19 2019-07-25 Cado Biotechnology Ivs N-pyrimidinyl hydroxy pyrazole derivatives and uses thereof
TW202140444A (zh) * 2020-03-20 2021-11-01 美商阿克比治療有限公司 Ｐｈｄ抑制劑化合物、組成物及使用方法
AR121621A1 (es) * 2020-03-20 2022-06-22 Akebia Therapeutics Inc Compuestos inhibidores de phd, composiciones y métodos de uso

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1112984B (de) * 1956-06-27 1961-08-24 Sandoz Ag Verfahren zur Herstellung von Pyrazolonderivaten
GB1115887A (en) * 1965-04-23 1968-05-29 Daiichi Seiyaku Company Ltd A substituted 3-pyrazoline-5-one and a 5-alkoxy derivative thereof
JPS565748B2 (ja) * 1972-09-01 1981-02-06
US4032646A (en) * 1973-04-17 1977-06-28 Bayer Aktiengesellschaft Pyrazol-5-ones
FR2529786A1 (fr) * 1982-07-12 1984-01-13 Nativelle Sa Ets Compositions pharmaceutiques a base de derives de la pyrazolone-5, nouveaux produits et procede de preparation
DE3419127A1 (de) * 1984-05-23 1985-11-28 Bayer Ag, 5090 Leverkusen 1-heteroaryl-4-aryl-pyrazolin-5-one
DE3430511A1 (de) * 1984-08-18 1986-02-27 Bayer Ag, 5090 Leverkusen Waschbestaendige, antimikrobiell wirksame fasern und faeden und ihre herstellung

Also Published As

Publication number Publication date
JPS61137878A (ja) 1986-06-25
DE3443308A1 (de) 1986-05-28
IL77138A0 (en) 1986-04-29
ES549299A0 (es) 1987-12-16
US4698344A (en) 1987-10-06
EP0183159A2 (de) 1986-06-04
EP0183159A3 (de) 1987-01-14
ES8801243A1 (es) 1987-12-16

Similar Documents

Publication Publication Date Title
GB8517577D0 (en) Medicaments
GB2153678B (en) Pharmaceutical composition
ZA853823B (en) Pharmaceutical composition
ZA859065B (en) 1-heteroaryl-4-aryl-pyrazolin-5-ones for use as medicaments
GB8426152D0 (en) Medicinal compositions
DE3567374D1 (en) Composition for ophthalmological use
GB2153677B (en) Pharmaceutical composition
GB8500504D0 (en) Pharmaceutical forms
GB8513641D0 (en) Pharmaceutical composition
GB8523490D0 (en) Medicinal composition
GB8508000D0 (en) Drug combinations
GB8525673D0 (en) Pharmaceutical agent
GB8521395D0 (en) Medicament
GB8429340D0 (en) Medicaments
GB8430072D0 (en) Pharmaceutical compounds
GB8509165D0 (en) Pharmaceutical agent
GB2153676B (en) Pharmaceutical composition
GB8419245D0 (en) Medicinal compositions
GB8518565D0 (en) Pharmaceutical composition
GB8510673D0 (en) Drug combinations
GB8422135D0 (en) Medicament
GB8412503D0 (en) Pharmaceutical compounds
GB8414776D0 (en) Pharmaceutical compounds
GB8726328D0 (en) Pharmaceutical compounds
GB8414775D0 (en) Pharmaceutical compounds